Lansen Pharmaceutical : CLARIFICATION ANNOUNCEMENT REVISED VOLUNTARY ANNOUNCEMENT IN RESPECT OF THE INFLUENCE OF THE NOVEL CORONAVIRUS

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 503)

CLARIFICATION ANNOUNCEMENT

REVISED VOLUNTARY ANNOUNCEMENT IN RESPECT OF THE

INFLUENCE OF THE NOVEL CORONAVIRUS

Reference is made to the two voluntary announcements of Lansen Pharmaceutical Holdings Limited (the "Company", together with its subsidiaries shall be referred to as the "Group") dated 11 February 2020 in respect of the influence of the Novel Coronavirus to the Group's business operation (the "Original Announcement" and the "Revised Announcement" respectively).

The Company would like to clarify that the following paragraph was inadvertently omitted in the second paragraph of the Original Announcement:

"The majority of the Group's operations are based in China and a number of restrictions have been imposed by provincial and national government to limit travel within China and to extend the Chinese New Year holiday period, in an attempt to control the spread of the Novel Coronavirus."

To ratify the omission, the Revised Announcement containing the above paragraph has been published shortly after the publication of the Original Announcement on 11 February 2020. The Revised Announcement supersedes the Original Announcement.

By order of the Board

Lansen Pharmaceutical Holdings Limited

Wu Zhen Tao

Chairman

Hong Kong, 12 February 2020

As at the date of this announcement, the executive managing Director is Mr. Chen Li; the non-executive Directors are Mr. Wu Zhen Tao, Mr. Stephen Burnau Hunt and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Fritz Heinrich Horlacher and Mr. Yeung Tak Bun, Allen.

1